8-K: Autolus Therapeutics Reports $9.0 Million in Q1 2025 AUCATZYL Net Product Revenue and Announces UK Marketing Authorization

Autolus Therapeutics announces Q1 2025 financial results, including $9.0 million in AUCATZYL net product revenue, and highlights regulatory approval in the UK and progress in autoimmune disease trials.

Summary

• Autolus Therapeutics reported Q1 2025 net product revenue of $9.0 million from AUCATZYL.
• The UK MHRA granted conditional marketing authorization for AUCATZYL for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL).
• Encouraging preliminary data was reported from the Phase 1 CARLYSLE trial in systemic lupus erythematosus (SLE).
• A Phase 2 pivotal clinical trial in lupus nephritis (LN) and a Phase 1 clinical trial in progressive forms of multiple sclerosis (MS) are planned to initiate before year-end 2025.
• The company has 39 centers fully activated in the U.S. as of May 7, 2025.
• Patient access to AUCATZYL continues to increase, with coverage secured for approximately 90% of total U.S. medical lives.
• The company expects to receive notification of approval status from the European Medicines Agency (EMA) in the second half of 2025 for Obe-cel.
• Research and development expenses decreased from $30.7 million to $26.7 million for the three months ended March 31, 2025, compared to the same period in 2024.
• Selling, general and administrative expenses increased from $18.2 million to $29.5 million for the three months ended March 31, 2025, compared to the same period in 2024.
• Net loss was $70.2 million for the three months ended March 31, 2025, compared to $52.7 million for the same period in 2024.
• Cash, cash equivalents and marketable securities at March 31, 2025, totaled $516.6 million, as compared to $588.0 million at December 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the successful launch of AUCATZYL, regulatory approval in the UK, and promising clinical data in autoimmune diseases. However, increased net losses and decreased cash reserves temper the overall outlook.

Positives

• AUCATZYL achieved $9.0 million in net product sales in Q1 2025, indicating a strong start to its commercial launch.
• The MHRA granted conditional marketing authorization for AUCATZYL in the UK, expanding its market reach.
• Preliminary data from the CARLYSLE trial showed promising results for obe-cel in treating SLE, with complete renal response in some patients.
• The company has aligned with the FDA on a Phase 2 trial design for lupus nephritis, potentially accelerating the path to approval.
• Approximately 90% of total U.S. medical lives are covered for patient access to AUCATZYL, ensuring broad patient access.
• The company is well capitalized with $516.6 million in cash, cash equivalents, and marketable securities to support its commercial and clinical activities.

Negatives

• Cost of sales for the three months ended March 31, 2025 totaled $18.0 million.
• The company experienced a net loss of $70.2 million for the three months ended March 31, 2025, compared to a net loss of $52.7 million for the same period in 2024.
• Cash, cash equivalents and marketable securities decreased from $588.0 million at December 31, 2024 to $516.6 million at March 31, 2025.

Risks

• The company's ability to generate revenues from AUCATZYL is dependent upon maintaining significant market acceptance among physicians, patients and healthcare payors.
• Payor reimbursement determinations and other market conditions could affect the company's ability to recognize revenue from AUCATZYL sales.
• The company faces risks related to obtaining and maintaining regulatory approval for obe-cel in additional territories.
• Delays in current or planned clinical trials could impact the company's development timeline.
• The company's product candidates may not be safe or effective, and may not receive regulatory approval.
• Competition with respect to market opportunities could impact the company's commercial success.
• A delayed cash receipt of approximately $20 million in R&D tax credit expected from the UK HMRC impacted cash flow.

Future Outlook

Autolus anticipates several milestones, including longer-term follow-up data from the FELIX clinical trial, notification from the EU regarding MAA decision in adult r/r ALL, initial data from the PY01 trial in pediatric ALL, presentation of SLE Phase 1 trial data, and dosing the first patient in Phase 2 trial in lupus nephritis and Phase 1 trials in progressive MS and AL amyloidosis by year-end 2025.

Management Comments

• We had a great first quarter of launch and are highly encouraged by physician enthusiasm for AUCATZYL in the U.S. We believe this speaks to the product profile and significant unmet need for patients, said Dr. Christian Itin, Chief Executive Officer of Autolus.
• Building on that momentum in the U.S., we recently obtained marketing authorization from the UKs MHRA, and we are working in collaboration with National Institute for Health and Care Excellence (NICE) to bring this much-needed therapy to patients in the UK.
• Our goal to expand into new markets is underpinned by our proprietary manufacturing and commercial infrastructure which has positioned us for strong execution.

Industry Context

Autolus's progress with AUCATZYL and obe-cel in CAR T-cell therapy aligns with the growing interest in targeted immunotherapies for cancer and autoimmune diseases. The company's expansion into autoimmune indications like lupus nephritis and multiple sclerosis reflects a broader trend in the industry to leverage CAR T-cell technology beyond oncology.

Comparison to Industry Standards

• The $9.0 million in net product sales for AUCATZYL in its first quarter of launch is a positive sign, but it's important to compare this to the launch trajectories of other CAR T-cell therapies like Novartis's Kymriah and Gilead's Yescarta.
• The 90% coverage of U.S. medical lives is competitive, as securing reimbursement is a major hurdle for CAR T-cell therapies.
• The clinical data from the CARLYSLE trial in SLE is encouraging, but further data and larger trials are needed to compare obe-cel's efficacy to existing treatments like belimumab and voclosporin.
• Autolus's plans to initiate trials in lupus nephritis and multiple sclerosis position it to compete with companies like Bristol Myers Squibb and Roche, which are also exploring CAR T-cell therapies for autoimmune diseases.

Stakeholder Impact

• Shareholders: The report provides insights into the company's financial performance and progress in clinical development, which can influence investment decisions.
• Employees: The report highlights the company's growth and expansion, which can impact job security and career opportunities.
• Patients: The report provides updates on the development and availability of new therapies, which can offer hope for improved treatment outcomes.
• Healthcare providers: The report provides information on the clinical data and reimbursement status of AUCATZYL, which can inform treatment decisions.
• Creditors: The report provides information on the company's financial stability and ability to meet its obligations.

Next Steps

• Share longer-term follow-up data from the FELIX study in the second quarter.
• Announce data from the pediatric PY1 trial in the second half of the year.
• Present full data with longer term follow-up from the Phase 1 CARLYSLE clinical trial at a medical conference in the second half of 2025.
• Dose the first patient in a Phase 2 trial for lupus nephritis before the end of 2025.
• Dose the first patient in a Phase 1 dose escalation study for progressive MS by year-end 2025.
• Expect to dose first patient in Phase 1 trial in AL amyloidosis By year-end 2025.

Key Dates

Keywords

AUCATZYL, obe-cel, Autolus Therapeutics, B-ALL, Lupus Nephritis, Multiple Sclerosis, CAR T-cell therapy, Financial Results, MHRA, EMA